D8Y0 Stock Overview
Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Sandoz Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 42.60 |
| 52 Week High | CHF 43.80 |
| 52 Week Low | CHF 25.80 |
| Beta | 0 |
| 11 Month Change | 5.97% |
| 3 Month Change | 9.23% |
| 1 Year Change | 60.15% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 62.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| D8Y0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.4% | -5.0% | -1.3% |
| 1Y | 60.2% | -22.0% | 7.4% |
Return vs Industry: D8Y0 exceeded the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: D8Y0 exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| D8Y0 volatility | |
|---|---|
| D8Y0 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: D8Y0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine D8Y0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1886 | 22,633 | Richard Saynor | www.sandoz.com |
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms.
Sandoz Group AG Fundamentals Summary
| D8Y0 fundamental statistics | |
|---|---|
| Market cap | €19.13b |
| Earnings (TTM) | -€7.68m |
| Revenue (TTM) | €9.71b |
2.0x
P/S Ratio-2,490x
P/E RatioIs D8Y0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D8Y0 income statement (TTM) | |
|---|---|
| Revenue | US$10.11b |
| Cost of Revenue | US$5.54b |
| Gross Profit | US$4.57b |
| Other Expenses | US$4.58b |
| Earnings | -US$8.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 05, 2025
| Earnings per share (EPS) | -0.018 |
| Gross Margin | 45.20% |
| Net Profit Margin | -0.079% |
| Debt/Equity Ratio | 49.5% |
How did D8Y0 perform over the long term?
See historical performance and comparison